US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cerenome, Inc

2.33

-0.0650-2.72%

Post-market: 2.340.0150+0.65%19:55 EDT

Volume:79.99K

Turnover:192.28K

Market Cap:17.65M

PE:-0.53

High:2.49

Open:2.40

Low:2.31

Close:2.39

52wk High:23.43

52wk Low:2.31

Shares:7.59M

Float Shares:6.46M

Volume Ratio:1.29

T/O Rate:1.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.3700

EPS(LYR):-7.2500

ROE:-614.05%

ROA:-135.36%

PB:3.23

PE(LYR):-0.32

Loading ...

Overview Company News Filings

Cerenome Price Target Cut to $43.00/Share from $57.00 by Ascendiant Capital

Cerenome Secures up to $20 Million Senior Secured Facility from 3i Fund with Royalty-Based Repayment

Cerenome Announces up to $20 Million Financing Facility with Royalty-Based Repayment

THOMSON REUTERS

Calendar of U.S. Earnings Expected in the Week Ahead

Cerenome Q2 EPS $(1.31) Misses $(0.85) Estimate, Sales $411.000K Miss $1.110M Estimate

Benzinga Earnings

Plus Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Press Release: Cerenome Reports Second Quarter 2026 Financial Results and Business Update

Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding Cnside® Contracted Coverage to over 150 Million Covered Lives

THOMSON REUTERS

Plus Therapeutics Inc Expected to Post a Loss of 91 Cents a Share - Earnings Preview

Plus Therapeutics Amends Bylaws to Reflect Corporate Name Change to Cerenome

Plus Therapeutics to Trade on NASDAQ as Cerenome Under CNSY Ticker from Aug. 3

Press Release: Cerenome Launches as an Integrated CNS Oncology Company

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/CNSY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNSY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNSY\",,,,,undefined,":{"symbol":"CNSY","market":"US","secType":"STK","nameCN":"Cerenome, Inc","latestPrice":2.325,"timestamp":1789156800000,"preClose":2.39,"halted":0,"volume":79988,"hourTrading":{"tag":"盘后","latestPrice":2.34,"preClose":2.325,"latestTime":"19:55 EDT","volume":1899,"amount":4449.755,"timestamp":1789170908995,"change":0.015,"changeRate":0.006452,"amplitude":0.012903},"delay":0,"changeRate":-0.02719665271966525,"floatShares":6457200,"shares":7589600,"eps":-4.37005,"marketStatus":"Market Closed","change":-0.065,"latestTime":"09-11 16:00:00 EDT","open":2.4,"high":2.49,"low":2.31,"amount":192284.992924,"amplitude":0.075314,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.37005,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1134968400000,"exchange":"NASDAQ","adjPreClose":2.39,"preHourTrading":{"tag":"盘前","latestPrice":2.44,"preClose":2.39,"latestTime":"09:29 EDT","volume":2497,"amount":6057.1996276,"timestamp":1789133370139,"change":0.05,"changeRate":0.020921,"amplitude":0.058326},"postHourTrading":{"tag":"盘后","latestPrice":2.34,"preClose":2.325,"latestTime":"19:55 EDT","volume":1899,"amount":4449.755,"timestamp":1789170908995,"change":0.015,"changeRate":0.006452,"amplitude":0.012903},"volumeRatio":1.2856830537855204},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNSY\",,,,,undefined,":{"symbol":"CNSY","floatShares":6457200,"roa":"-135.36%","roe":"-614.05%","lyrEps":-7.25,"volumeRatio":1.2856830537855204,"shares":7589600,"dividePrice":0,"high":2.49,"amplitude":0.075314,"preClose":2.39,"low":2.31,"week52Low":2.31,"pbRate":"3.23","psRate":"4.20","week52High":23.425,"institutionHeld":0.0916,"latestPrice":2.325,"eps":-4.37005,"divideRate":0,"volume":79988,"delay":0,"ttmEps":-4.37005,"open":2.4,"prevYearClose":12.8075,"prevWeekClose":2.755,"prevMonthClose":2.82,"prevQuarterClose":4.37,"fiveDayClose":2.98,"twentyDayClose":3.7,"sixtyDayClose":4.57},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNSY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"CNSY","fiscalQuarterEnding":"2026/06","expectedEps":-0.96,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"post","actualEps":-1.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNSY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNSY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1775016000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CNSY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CNSY","date":"2026-09-11","current":-0.532031,"percent":1,"low":-2.284561,"twenty":-2.209563,"median":-0.887318,"eighty":-0.808178,"high":-0.695308,"avg":-1.305257,"sd":0.647704,"marketCap":18139203},"quantilePoints":[{"date":"2026-08-07","current":-2.22687,"twenty":-2.261485,"median":-2.232639,"eighty":-2.18764,"marketCap":26568789},{"date":"2026-08-14","current":-2.134565,"twenty":-2.237254,"median":-2.212448,"eighty":-2.134565,"marketCap":25467492},{"date":"2026-08-21","current":-0.791526,"twenty":-2.228024,"median":-2.134565,"eighty":-0.843766,"marketCap":20649318},{"date":"2026-08-28","current":-0.901864,"twenty":-2.21764,"median":-1.50083,"eighty":-0.857767,"marketCap":23527837},{"date":"2026-09-04","current":-0.866953,"twenty":-2.210717,"median":-0.8975,"eighty":-0.843766,"marketCap":22617082},{"date":"2026-09-11","current":-0.695308,"twenty":-2.209563,"median":-0.887318,"eighty":-0.808178,"marketCap":18139203}],"updateTime":1789219838617},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNSY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666253295","title":"Cerenome Price Target Cut to $43.00/Share from $57.00 by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253295","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253295?lang=en_us&edition=fundamental","pubTime":"2026-09-11 18:11","pubTimestamp":1789121460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNSY/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNSY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560193","title":"Cerenome Secures up to $20 Million Senior Secured Facility from 3i Fund with Royalty-Based Repayment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560193?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:15","pubTimestamp":1789038936,"startTime":"0","endTime":"0","summary":"Cerenome secures up to $20 million senior secured facility from 3i Fund with royalty-based repaymentCerenome entered a senior secured financing agreement with 3i Fund for a facility of up to USD 20 mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL2WzxDy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","LU2210150020.SGD","SG9999014005.SGD","IE00BQXX3C00.GBP","SG9999014039.USD","SG9999014021.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","BK4585","BCDF","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","NDAQ","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","CNSY","LU2095319765.USD","LU0314104364.USD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560156","title":"Cerenome Announces up to $20 Million Financing Facility with Royalty-Based Repayment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560156?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:15","pubTimestamp":1789038900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA9WY85K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CNSY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660891784","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2660891784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660891784?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:00","pubTimestamp":1786960800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·Amer Sports Inc.                                  2Q       .11    6:00 AM. ·Home Depot Inc.                                   2Q      4.73    6:00 AM. ·Pony AI ADR                                     2Q      (.15)   5:00 AM. ·BILL Hldgs Inc                                  4Q       .71    4:01 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LYTS","AAP","FLO","FLUX","ATAT","BILL","MBRX","IMTX","LZB","MRCY","ADIL","FUTU","CNSY","DOMO","BABA","ZTO","CAAP","BJ","ATHM","DE","GGAL","ANVS","BIDU","HAIN","BEKE","NDSN","KEYS","AS","FBRX","JKHY","HTHT","ADI","BMA","FLNG","FN","BEEM","EL","ANF","HD","COTY","KC","LOW","KLAR","MRKR","HSAI","XP","IQ","ALVO","DCGO","LONA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659041121","title":"Cerenome Q2 EPS $(1.31) Misses $(0.85) Estimate, Sales $411.000K Miss $1.110M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659041121","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659041121?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:12","pubTimestamp":1786741958,"startTime":"0","endTime":"0","summary":"Cerenome (NASDAQ:CNSY) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.85) by 54.12 percent. This is a 718.75 percent decrease over losses of $(0.16) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61231587/cerenome-q2-eps-1-31-misses-0-85-estimate-sales-411-000k-miss-1-110m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Cerenome Q2 EPS $(1.31) Misses $(0.85) Estimate, Sales $411.000K Miss $1.110M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659412153","title":"Plus Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659412153","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659412153?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:46","pubTimestamp":1786740367,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryPlus Therapeutics IncCNSY.OQreported a quarterly adjusted loss of $1.31 per share for the quarter ended June 30, l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B1KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNSY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659412930","title":"Press Release: Cerenome Reports Second Quarter 2026 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659412930","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659412930?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:15","pubTimestamp":1786738500,"startTime":"0","endTime":"0","summary":"August 3, 2026, with the Company's common stock trading on the Nasdaq. Capital Market under the ticker symbol \"CNSY\"REYOBIQ Development-- Continued enrollment in the ReSPECT-LM multiple-dose clinical trial. As. of June 30, 2026, approximately one-third of patients had been enrolled,with no dose-limiting toxicities observed to date, supporting the. development of a recommended Phase 2 dose/dosing regimen by year-end. -- Continued enrollment in the ReSPECT-GBM Phase 2 trial. Current enrollment. rates indicate full enrollment in 2026 followed by a data readout and a. subsequent End-of-Phase 2 meeting with the U.S. Food and Drug. -- Initial site activation of the ReSPECT-PBC pediatric brain cancer Phase 1. trial at Lurie Children's Hospital. First dosing expected in the third. -- Continued commercial-level manufacturing scale-up and supply chain. enhancement for REYOBIQ drug supplyCNSide CSF Assay Platform-- Performed 232 CNSide cerebrospinal fluid tests during the first half of. 2026 and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","BK4232","BK4604","NCI","BK4555","BK4202","TM","BK4099","BK4139","R","BK4585","CNSY","BK4022","LCLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159181","title":"Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding Cnside® Contracted Coverage to over 150 Million Covered Lives","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159181?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUAB71BNS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CNSY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658893993","title":"Plus Therapeutics Inc Expected to Post a Loss of 91 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893993","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893993?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:49","pubTimestamp":1786366145,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc <CNSY.OQ> expected to post a loss of91cents a share - Earnings PreviewPlus Therapeutics IncCNSY.OQCNSY.Ois expected to  show a fall in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44710O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNSY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657876560","title":"Plus Therapeutics Amends Bylaws to Reflect Corporate Name Change to Cerenome","url":"https://stock-news.laohu8.com/highlight/detail?id=2657876560","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657876560?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:33","pubTimestamp":1785879239,"startTime":"0","endTime":"0","summary":"Plus Therapeutics amends bylaws to reflect corporate name change to CerenomePlus Therapeutics amended its bylaws to reflect a corporate name change to Cerenome, effective Aug. 3, 2026.Nasdaq trading s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL2PyX3w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655366725","title":"Plus Therapeutics to Trade on NASDAQ as Cerenome Under CNSY Ticker from Aug. 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2655366725","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655366725?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:32","pubTimestamp":1785501155,"startTime":"0","endTime":"0","summary":"Plus Therapeutics to trade on Nasdaq as Cerenome under CNSY ticker from Aug. 3Plus Therapeutics will complete its rebrand to Cerenome on Aug. 3, 2026.Nasdaq Capital Market trading will switch to ticke","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL6DlsRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014005.SGD","PSTV","LU2210149790.SGD","NDAQ","SG9999014021.USD","BK4585","LU0314104364.USD","BK4112","BCDF","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BN0W2T93.GBP","BK4588","SG9999014013.SGD","IE00BKPKM429.USD","BK4139","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BGHQF748.EUR","CNSY","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655366743","title":"Press Release: Cerenome Launches as an Integrated CNS Oncology Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2655366743","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655366743?lang=en_us&edition=fundamental","pubTime":"2026-07-31 20:30","pubTimestamp":1785501000,"startTime":"0","endTime":"0","summary":"cellular and multiomic characterization of cerebrospinal fluid for the. diagnosis and management of patients with or at risk for CNS cancers. targeted radiotherapeutic being evaluated in clinical trials for. cancer, designed to deliver targeted radiation directly to CNS tumors. -- The Company's data analytics and artificial intelligence platform is a. proprietary and multifaceted initiative designed to integrate diverse. data sets into actionable insights that support precision oncology,therapeutic development, and clinical decision-makingFor patients, this integrated approach has the potential to enable earlier detection, more informed treatment decisions, disease monitoring and ultimately better outcomes. For healthcare providers, Cerenome can offer a more comprehensive systems view of the disease from diagnostic interrogation to longitudinal patient management. For academic and biopharmaceutical partners, the platform","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4604","BK4232","BK4099","03160","BK4588","BK4139","BK4022","BMED","TM","R","PSTV","CNS","CNSY","CSF","BK4555","LCLG","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004372","title":"Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004372","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654004372?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":"Posters will highlight research across the Company’s REYOBIQ clinical development program and CNSide cerebrospinal fluid diagnostic platformHOUSTON, July  28, 2026  (GLOBE NEWSWIRE) -- Plus Therapeuti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334137/0/en/Plus-Therapeutics-Announces-Scientific-Presentations-and-Sponsored-Symposium-at-2026-SNO-ASCO-CNS-Metastases-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTV","CNSY","BK4135","BK4007","CSF","CNS","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}